Nhua Pharmaceutical released its 2026 half-year report. Net profit attributable to the parent in the first half was 741 million yuan, up 5.7% year on year. Operating revenue was 3.218 billion yuan, up 6.9% year on year. Net profit attributable to the parent after deducting non-recurring items was 746 million yuan, up 6.7% year on year. Net operating cash flow was 280 million yuan, down 43.3% year on year. Second-quarter operating revenue was 1.61 billion yuan, up 7.3% year on year, and net profit attributable to the parent was 423 million yuan, up 5.9% year on year. The company said its main business is pharmaceutical research and development, production and sales. In particular, it maintained stability in central nervous system products, increased research and development investment, and advanced the layout of its new product pipeline.
Jiangsu Nhwa Pharmaceutical Co LtdFirst-half net profit up 5.7% and revenue up 6.9%, beating expectations.
